GTx-758 is an oral luteinizing hormone (LH) inhibitor developed for the treatment of advanced prostate cancer.

Preclinical in vitro and in vivo data suggest GTx-758 rapidly suppresses secretion of LH, by feedback inhibition on the pituitary gland, thereby inhibiting production of androgens by the testes. In preclinical models, GTx-758 has demonstrated its potential to achieve medical castration by reducing testosterone, considered as primary growth factor of prostate cancer.

According to researchers, common side effects caused by current androgen deprivation therapies (ADT) for prostate cancer, such as hot flashes, bone los, adverse lipid changes, are excluded by GTx-758 use.

We believe GTx-758, with an oral formulation and the potential to treat prostate cancer through suppression of testosterone without also causing bone loss and hot flashes could become best in class androgen deprivation therapy.

| 15.07.2009 |

Ipsen and GTx partnership

Ipsen (Paris:IPN) and GTx, Inc. (Nasdaq: GTXI) recently announced the expansion of their partnership for the development and commercialization.

This new agreement with GTx gives Ipsen expanded market reach and rights for toremifene, in what they view as significant unmet medical needs for patients suffering from prostate cancer. It will strengthen Ipsen’s franchise in hormone-dependent cancers and broaden our drug range in the oncology area

Under the terms of the amended collaboration agreement, GTx has granted Ipsen (among others) the first right of negotiation under certain conditions for rights to GTx-758, currently in Phase II clinical trial for the first-line treatment of men with advanced prostate cancer, in Ipsen’s licensed toremifene territories.

| 23.03.2010 |